Car-t cell therapy for Claudin 18.2 positive advanced tumors
Part of Cancer clinical trials.
This trial tests a special type of immune therapy called CAR-T, which uses your own blood cells to attack cancer cells that have a specific marker, Claudin 18.2. It may be an option for people with advanced solid tumors (especially pancreatic cancer) that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced cancer that has not responded to at least 2 prior treatments (or at least 1 prior treatment for advanced pancreatic cancer).
- Your tumor must test positive for a protein called Claudin 18.2.
- You must have measurable tumors (visible on scans).
- You need to be in fairly good physical shape (able to do most daily activities).
- You cannot have brain metastases, active infections, or certain other health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T) that targets a protein called Claudin18.2 found on some stomach, esophagus, and gastroesophageal junction cancers. The goal is to see if this treatment can shrink tumors or stop them from growing when other treatments have stopped working.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
This early-phase trial is testing a new kind of immune cell therapy—dendritic cells and CAR-T cells—that specifically targets a protein called Claudin18.2 on your cancer cells. It is for people with advanced pancreatic cancer who have already tried standard treatments.
This study tests a new treatment using your own immune cells (called CAR-T and CAR-DC) that are engineered to attack cancer cells with a specific protein (Claudin18.2). It is for people with advanced colorectal cancer who have exhausted standard treatments.
This trial tests a new treatment called CLDN18.2 CAR T cells in people with advanced solid tumors that have a specific marker (CLDN18.2). It aims to see if it is safe and works against cancers that have not responded to standard treatments.
Hear when a new Claudin18.2 Positive Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.